Every 10-Q that Immunome, Inc. (IMNM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IMNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMNM filings page.
Immunome, Inc. continued to operate as a clinical‑stage oncology biotech with no product revenue and a growing R&D footprint in the quarter ended June 30, 2026. The company reported a Q2 2026 net loss of $73.1 million and a six‑month net loss of $127.0 million, both wider than a year earlier, driven by higher research and development and commercialization‑readiness spending. Q2 collaboration revenue fell to zero after the AbbVie agreement ended in 2025.
Cash, cash equivalents and marketable securities totaled $520.0 million at June 30, 2026, with management stating this should fund current and planned operations for at least 12 months from the report’s filing date. Operating cash outflow was $120.3 million for the first half of 2026. The pipeline advanced, with varegacestat’s NDA accepted by the FDA and assigned an April 28, 2027 PDUFA date, and multiple antibody‑drug conjugate and radioligand programs in Phase 1 trials or IND‑enabling work.
Immunome, Inc. reported a larger net loss as it accelerated investment in its oncology pipeline but ended the quarter with substantial cash. For the three months ended March 31, 2026, net loss was $53.8 million versus $41.6 million a year earlier, driven mainly by higher research and development spending of $46.4 million and general and administrative expenses of $13.0 million. There was no collaboration revenue, compared with $2.9 million in the prior-year period, after the AbbVie agreement ended in 2025.
Cash and cash equivalents were $582.7 million as of March 31, 2026, supported by 2025 equity raises and an at-the-market program, which management expects will fund operations for at least 12 months from the report filing date. The company advanced several key programs: it submitted a new drug application for desmoid tumor candidate varegacestat, received IND clearance for ADC IM-1617, initiated a Phase 1 trial for radioligand therapy IM-3050, and continues Phase 1 development of ADC IM-1021 and IND-enabling work on preclinical ADCs IM-1340 and IM-1335.
Immunome (IMNM) reported Q3 2025 results showing a net loss of $57.5 million as collaboration revenue dropped to zero after its AbbVie agreement terminated in July 2025. Operating expenses rose to $60.1 million, driven by research and development of $49.2 million and general and administrative of $10.9 million.
Cash and cash equivalents were $272.6 million at September 30, 2025, up from $143.4 million at year-end, reflecting a January 2025 public offering and sales under its at-the-market program. Total liabilities were $35.5 million and stockholders’ equity was $263.9 million. The company states its cash is sufficient to fund operations for at least 12 months from the filing date.
Year to date, net loss improved to $142.5 million from $212.7 million in 2024 as in‑process R&D charges subsided. In January 2025, Immunome issued 22,258,064 shares for net proceeds of $161.7 million. During Q3 2025 it sold 4,625,156 shares via ATM for gross proceeds of $45.9 million; $134.1 million capacity remained at quarter end. Common shares outstanding were 91,710,277 as of November 3, 2025. The pipeline advanced with a Phase 3 trial of varegacestat (topline data expected in the second half of 2025) and ongoing early-stage programs.